{"filings":[{"id":1334036,"accession_number":"0001490978-26-000059","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2026-06-29T20:29:15+00:00","items":["7.01"],"status":"ready","headline":"Schrödinger receives $57M from Lilly's acquisition of co-founded Ajax Therapeutics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Received ~$57M cash from Eli Lilly's acquisition of Ajax Therapeutics, a company co-founded by Schrödinger.","Eligible for additional cash payments upon achievement of specified clinical and regulatory milestones by Ajax.","Acquisition completed June 29, 2026; Ajax is a biotech company co-founded by Schrödinger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1222277,"accession_number":"0001490978-26-000049","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2026-06-23T20:10:58+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Schrödinger shareholders approve 3M share increase to equity plan, elect directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2022 Equity Incentive Plan, increasing authorized shares by 3,000,000.","Richard A. Friesner, Rosana Kapeller-Libermann, and Gary Sender elected as Class III directors for three-year terms.","Non-binding advisory vote on executive compensation approved: 51.3M shares for, 0.87M against.","Ratification of KPMG LLP as independent auditor for FY2026 approved with 61.7M shares for.","Common stock and limited common stock voted together on proposals except director election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":918756,"accession_number":"0001490978-26-000045","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2026-06-08T20:22:56+00:00","items":["5.02","9.01"],"status":"ready","headline":"Schrödinger details separation terms with former CCO Mannix Aklian: 9-month salary, $88k bonus, RSU acceleration","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Separation effective May 29, 2026; transition period as Senior Advisor ended.","Receives base salary continuation for 9 months, plus COBRA premiums for 12 months.","Gross bonus of $88,096 for Q1/Q2 2026 and prorated annual bonus.","Acceleration of 3,515 RSUs originally scheduled to vest July 2026.","Restrictive covenants (non-compete, non-solicit) extended 12 months post-separation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":554877,"accession_number":"0001490978-26-000041","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2026-05-20T20:19:47+00:00","items":["5.02","7.01"],"status":"ready","headline":"Schrodinger CCO Mannix Aklian departs; Paul Davie returns as interim; guidance reaffirmed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mannix Aklian ceased as Chief Commercial Officer, Global Head of Software Sales effective May 18, 2026.","Paul Davie, former EVP Sales, returns as interim CCO; company conducting search for permanent replacement.","Company reaffirms full-year and Q2 2026 financial and operational guidance provided on May 5, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93156,"accession_number":"0001490978-26-000036","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrödinger Q1 ACV $28.4M (+12%), drug disc. rev surges to $22.9M, net loss $60M, FY guide maintained","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ACV $28.4M (+12% YoY); software revenue $35.6M (-21%) reflecting hosted transition.","Drug discovery revenue surged to $22.9M from $10.2M on deferred revenue recognition and program discontinuation.","Net loss $60.0M vs $59.8M; cash and securities $406M.","Maintained FY2026 guidance: ACV $218-228M (10-15% growth), drug discovery revenue $55-65M.","Planned summer launch of Bunsen agentic AI co-scientist; Lilly's $2.3B Ajax acquisition validates platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":58587000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104548,"accession_number":"0001490978-26-000013","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Schrödinger appoints Therese Abrams as principal accounting officer; Herman transitions out","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Therese Abrams designated principal accounting officer effective March 8, 2026; she was VP, Corporate Controller since July 2025.","Abrams previously held finance roles at Schrödinger since 2013; earlier at Jive Software and KPMG; she is a CPA.","Jenny Herman ceased as Chief Accounting Officer and principal accounting officer on March 6, 2026; remains employed through April 10, 2026.","No family relationships or disclosable transactions involving Abrams; standard indemnification agreement executed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104547,"accession_number":"0001490978-26-000009","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrödinger reports 2025 revenue $255.9M (+23%), net loss $103.3M; guides 2026 software ACV $218-228M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Software revenue $199.5M (+10.6%); drug discovery revenue $56.4M (+107%) vs $27.2M in 2024.","Software ACV $198.5M, up 4% YoY; net loss $103.3M vs $187.1M; adjusted EBITDA -$114.9M vs -$152.5M.","Accelerating transition to hosted software; GAAP software revenue expected to decline short-to-medium term while ACV unchanged.","2026 guidance: software ACV $218-228M (10-15% growth), drug discovery rev $55-65M, opex below 2025.","2028 objective: positive adjusted EBITDA by year-end, substantially complete hosted transition, drug discovery rev ~$50M/year."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":255869000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120824,"accession_number":"0001490978-25-000116","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrödinger Q3 revenue up 54% to $54.3M; software growth 28%, FY guidance trimmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $54.3M (+54% YoY); software revenue $40.9M (+28%); drug discovery $13.5M.","GAAP net loss narrowed to $32.8M from $38.1M; non-GAAP net loss $42.3M (was $63.7M).","FY2025 software revenue growth guidance cut to 8-13% (from 10-15%); drug discovery raised to $49-52M.","Shift to discovery-focused R&D; not advancing programs independently, expects ~$70M savings.","SGR-1505 got Orphan Drug Designation; SGR-6016 selected as development candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":168634000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137427,"accession_number":"0001490978-25-000106","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Schrödinger finalizes separation agreement with former CFO Geoffrey Porges","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Separation date June 6, 2025; receives nine months base salary of $487,500.","COBRA premium payments for up to 12 months; prorated 2025 bonus of $134,543.","Accelerated vesting of 56,250 options; exercise period for 238,913 options extended to 12 months.","Mutual release of claims; confidentiality, non-disparagement, and cooperation obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137426,"accession_number":"0001490978-25-000099","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrödinger Q2 revenue $54.8M (+16% YoY); narrows net loss; maintains revenue guidance, lowers expense guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $54.8M (+16% YoY); software revenue $40.5M (+15%); drug discovery $14.2M (+19%).","Net loss improved to $43.2M from $54.0M; non-GAAP net loss $47.5M.","Guidance: Software revenue growth 10-15% reaffirmed; op. expenses expected lower than 2024; cash burn significantly lower.","SGR-1505 FDA Fast Track; initial Phase 1 data presented; exploring strategic options; SGR-2921/SGR-3515 data Q4 2025.","May 7% workforce reduction expected to save ~$30M annually; new CFO Richie Jain appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":114310000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154747,"accession_number":"0001490978-25-000082","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Schrödinger stockholders elect all directors, approve say-on-pay and auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class II directors elected: Chodakewitz, Lynton, Thornberry, van Kralingen.","Michael Lynton received 32.4M for and 12.3M against (27.5% against).","Say-on-pay passed: 50.8M for, 3.0M against; limited common stock voted unanimously for.","Ratification of KPMG as independent auditor for FY2025 approved: 61.4M for, 0.3M against.","Broker non-votes on director election: 7.9M shares; no other proposals had broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154746,"accession_number":"0001193125-25-122800","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Schrodinger appoints Richie Jain as CFO; Geoffrey Porges departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richie Jain named EVP and CFO effective May 16, 2025; previously SVP Strategic Finance.","Annual base salary of $535,000; target bonus of 55% of base for 2025 prorated.","Equity grant: 18,750 options and 9,375 RSUs, vesting over 4 years.","Former CFO Geoffrey Porges leaves role, stays as advisor through June 6, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154745,"accession_number":"0001193125-25-122461","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Schrödinger restructures, cuts ~60 jobs (7% of workforce) to reduce cash burn","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduces headcount by ~60 employees (~7% of full-time workforce) effective May 19, 2025.","Estimates $3M in restructuring charges (severance, benefits) in FY2025.","Expects annualized operating expense savings of ~$30M; about half from headcount reduction.","Restructuring aims to improve cash burn rate and operational efficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154744,"accession_number":"0001490978-25-000058","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrödinger Q1 total revenue $59.6M (+63% YoY); software rev $48.8M; maintains FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Software revenue $48.8M (+46% YoY); drug discovery revenue $10.7M (+237%) incl $5.7M from Novartis collaboration.","GAAP net loss $59.8M vs $54.7M; non-GAAP net loss improved to $46.7M from $62.4M.","FY 2025 guidance reaffirmed: software rev growth 10-15%, drug discovery rev $45-50M, opex growth <5%.","Initial Phase 1 data for SGR-1505 (MALT1 inhibitor) expected in June; SGR-2921 (CDC7) and SGR-3515 (Wee1/Myt1) data in H2 2025.","Bridget van Kralingen appointed to Board of Directors; predictive toxicology initiative on track for H2 2025 launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":59551000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154743,"accession_number":"0001490978-25-000034","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Schrödinger settles derivative suit over director pay; adopts compensation reforms","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Company adopted new director comp policy capping each element at 60th percentile of peer group.","Settlement requires retention of independent compensation consultant for annual peer analysis.","Company to pay $390,000 in attorneys' fees; no admission of wrongdoing by defendants.","Court approval hearing scheduled for June 18, 2025 in New York Supreme Court.","Governance reforms must be maintained for at least four years from adoption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173255,"accession_number":"0001490978-25-000026","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":[],"status":"ready","headline":"Schrödinger elects Bridget van Kralingen to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bridget van Kralingen elected as class II director effective March 7, 2025.","She is Senior Partner at Motive Partners, formerly SVP at IBM.","Receives option for 17,050 shares at $21.02 and 10,000 restricted stock units.","Also serves on boards of Teradyne, Travelers, and Discovery Limited.","No material transactions or arrangements requiring disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173254,"accession_number":"0001490978-25-000013","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrödinger Q4 software revenue $79.7M (+16% YoY); 2025 outlook: rev growth 10-15%, drug disc rev $45-50M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 total revenue $88.3M (+19% YoY); software revenue $79.7M (+16% YoY).","Full-year 2024 net loss $187.1M vs net income $40.7M in 2023; non-GAAP net loss $191.4M.","Cash, equivalents, and marketable securities $367.5M at Dec 31, 2024; received $150M upfront from Novartis in Jan 2025.","2025 guidance: software revenue growth 10-15%; drug discovery revenue $45-50M; software gross margin 74-75%; OpEx growth <5%.","Expanded collaboration with Lilly (undisclosed target); Novartis collaboration cleared with $150M payment received."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":207539000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190276,"accession_number":"0001490978-24-000088","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrödinger Q3 total revenue $35.3M (-17% YoY); announces $150M upfront Novartis collaboration","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Software revenue $31.9M (+10% YoY); drug discovery revenue $3.4M (-75% YoY).","Net loss $38.1M vs $62.0M a year ago; non-GAAP net loss $63.7M.","Novartis pays $150M upfront; potential milestones up to $2.3B plus royalties.","2024 guidance: software rev growth 8-13%; drug discovery rev $20-30M; software gross margin slightly below 2023.","Cash & equivalents $398.4M at Sept 30, 2024; received $48M from Lilly buyout of Morphic."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":119222000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190275,"accession_number":"0001490978-24-000087","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Schrödinger enters $2.272B collaboration with Novartis; $150M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $150 million to be paid after HSR waiting period expires.","Eligible for up to $892M in discovery/development milestones and $1.38B in commercial milestones across initial project plans.","Eligible for tiered royalties on net sales of collaboration products: mid-single-digit to low-double-digit percent, subject to reductions.","Research term for each project plan is generally four years; Novartis responsible for clinical development and commercialization.","Exclusivity provisions prevent Schrödinger from working on collaboration targets with third parties for specified period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206773,"accession_number":"0001490978-24-000078","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Schrödinger enters new master license agreement with Columbia University, consolidating eight prior IP licenses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective September 11, 2024, Schrödinger LLC and Columbia University executed a Master License Agreement, amending and restating eight prior license agreements.","Royalty rate for licensed products is a low single-digit percentage of Gross Revenues; royalty term is 20 years, extendable by 10 years per Columbia Improvement.","New terms include royalty on equity securities received as Services Project Income, with transfer obligations to Columbia upon compliance with securities laws.","Dr. Richard Friesner, Schrödinger co-founder and board member, invented some licensed technologies and receives a portion of royalties paid to Columbia.","Licensed products include key software: PS-GVB, Glide, PrimeX, QSite, Combiglide, Prime, and Membrane Permeability model."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206772,"accession_number":"0001490978-24-000071","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrödinger Q2 rev $47.3M (+35% YoY); net loss $54.0M; updates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $47.3M (+35% YoY), software rev $35.4M (+21%), drug discovery $11.9M (+104%). Net loss $54.0M vs income $4.3M YoY.","FY2024 guidance: software rev growth 6-13%, drug discovery $30-35M, op expense growth 8-10%, cash use above FY2023.","Co-founded Morphic to be acquired by Lilly for ~$3.2B; Schrödinger holds 834,968 shares and low single-digit royalties.","Launched predictive toxicology platform with $10M Gates Foundation grant and NVIDIA AI integration.","Pipeline: SGR-1505 Phase 1 data 1H25; SGR-2921 Fast Track, data 2H25; SGR-3515 Phase 1 started, data 2H25."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":83932000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224020,"accession_number":"0001490978-24-000051","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Schrödinger shareholders approve 5M share increase for 2022 Equity Plan","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Approved increase of 5,000,000 shares for 2022 Equity Incentive Plan; 413,155 shares for 2020 ESPP.","Class I directors Ramy Farid, Gary Ginsberg, Arun Oberoi elected for three-year term expiring 2027.","Advisory vote on executive compensation passed with ~52M shares for vs 1M against.","Amendment to certificate of incorporation to permit officer exculpation approved (50.9M for).","KPMG LLP ratified as independent auditor for FY 2024 (59.2M for, 550k against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224019,"accession_number":"0001490978-24-000045","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrödinger Q1 revenue $36.6M, net loss $54.7M; FDA clears IND for SGR-3515","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $36.6M (down 44% YoY); software revenue $33.4M (+3.7%).","Net loss $54.7M vs net income $129.1M in Q1 2023; non-GAAP net loss $62.4M.","FDA cleared IND for SGR-3515 (Wee1/Myt1 inhibitor); Phase 1 solid tumors trial expected Q3 2024.","SGR-1505 and SGR-2921 Phase 1 data readouts expected late 2024 or 2025.","Rights to SOS1 inhibitor reverted from BMS after portfolio prioritization."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":36598000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243385,"accession_number":"0001490978-24-000020","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Schrödinger enters ATM equity agreement with Leerink to sell up to $250M of common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $250M of common stock may be sold at-the-market through Leerink Partners under new Sales Agreement.","Agreement amends and restates prior May 2023 Sales Agreement; no shares sold under prior agreement.","Company will pay Leerink commissions up to 3% of gross proceeds and provide customary indemnification.","Shares will be issued under new shelf registration statement filed on February 28, 2024 (333-277479)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243384,"accession_number":"0001490978-24-000017","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrödinger Q4 software rev +44% to $68.7M; guides 6-13% software growth in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 software revenue $68.7M (+44% YoY); total revenue $74.1M (+30.4%); net loss $30.7M.","Full-year 2023 total revenue $216.7M (+19.7%); net income $40.7M vs $149.2M loss in 2022.","2024 guidance: software revenue growth 6-13%; drug discovery revenue $30-35M; expects higher cash burn.","Pipeline: Phase 1 data for MALT1 inhibitor SGR-1505 well tolerated; two clinical programs; Wee1/Myt1 IND expected H1 2024.","Total ACV grew 9.7% to $154.2M; customers with >$1M ACV rose from 18 to 27."],"consensus_eps_estimate":null,"consensus_eps_actual":0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":216666000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260774,"accession_number":"0001490978-23-000108","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrödinger Q3 revenue $42.6M (+15% YoY); net loss widens to $62M; updates guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $42.6M (+15% YoY); software revenue $28.9M (+17%); drug discovery $13.7M (+11%).","Net loss $62.0M vs $39.9M in Q3 2022; operating expenses rose 26% to $79.8M.","Updated FY2023 guidance: software revenue growth 15-18%; drug discovery $50-70M; cash from ops expected higher.","Pipeline: SGR-1505 healthy volunteer data due Q4; SGR-2921 Phase 1 started; PRMT5-MTA program disclosed.","Bristol Myers Squibb returned rights to two oncology programs; company maintains ~$503M cash."],"consensus_eps_estimate":null,"consensus_eps_actual":0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":142540000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278043,"accession_number":"0001490978-23-000095","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K/A","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrödinger Q2 revenue falls 8.5% to $35.2M; raises software guidance, cuts drug discovery outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income of $4.3M vs loss of $47.7M; non-GAAP net loss widened to $56.8M from $43.8M.","Total revenue $35.2M, down 8.5% YoY; drug discovery revenue fell 31% to $5.8M.","2023 software revenue growth guidance raised to 15-18%; drug discovery revenue guidance cut to $50-70M from $70-90M.","IND cleared for CDC7 inhibitor SGR-2921; Phase 1 trial in AML/MDS planned for 2023.","Margaret Dugan appointed CMO; Zai Lab collaboration not advanced, program wholly-owned."],"consensus_eps_estimate":null,"consensus_eps_actual":1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":99971000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278044,"accession_number":"0001490978-23-000089","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrödinger Q2 revenue $35.2M (-8.5% YoY); raises software revenue guidance, cuts drug discovery outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $4.3M vs net loss $47.7M YoY, driven by $45.0M other income and $20.4M tax benefit.","Non-GAAP net loss $56.8M vs $43.8M YoY; operating expenses rose 23.7% to $74.9M.","Software revenue growth guidance raised to 15%-18%; drug discovery revenue guidance cut to $50M-$70M from $70M-$90M.","IND cleared for CDC7 inhibitor SGR-2921; Phase 1 trial for AML/MDS expected in 2023.","Zai Lab elected not to continue discovery collaboration; program returned to wholly-owned by Schrödinger."],"consensus_eps_estimate":null,"consensus_eps_actual":1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":99971000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296120,"accession_number":"0001490978-23-000064","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Schrödinger stockholders elect three Class III directors, approve say-on-pay and auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Richard Friesner, Rosana Kapeller-Libermann, Gary Sender elected as Class III directors for three-year terms.","Advisory vote on executive compensation passed with 50.2M shares for, 2.9M against, 203k abstain.","Ratification of KPMG as independent auditor for FY 2023 passed with 59.0M shares for, 230k against.","Broker non-votes: 6.1M shares on director election and say-on-pay; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296119,"accession_number":"0001490978-23-000055","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2023-05-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Schrodinger enters $250M at-the-market stock offering with SVB Securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $250M in common stock may be sold through SVB Securities as sales agent.","SVB Securities will receive up to 3.0% commission on gross proceeds.","Shares will be sold under existing S-3ASR shelf registration; prospectus supplement filed May 24, 2023.","Offering may be suspended or terminated by either party; no use of proceeds disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296118,"accession_number":"0001490978-23-000047","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrödinger Q1 revenue $64.8M (+33%), net income $129.1M on $147M Nimbus gain","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Drug discovery revenue $32.6M (up 109% YoY) includes $25M BMS milestone for SOS1/KRAS program.","Software revenue $32.2M (down 3% YoY); gross margin 78%.","Cash from Nimbus TYK2 sale $147.3M; total cash and securities $532M at quarter-end.","Phase 1 dosing ongoing for SGR-1505 (MALT1) in B-cell malignancies and healthy volunteers.","Guidance reaffirmed: software revenue growth 13-17%, drug discovery $70-90M; operating expense growth to moderate."],"consensus_eps_estimate":null,"consensus_eps_actual":1.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":64782000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296117,"accession_number":"0001490978-23-000029","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2023-04-13T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Schrodinger amends bylaws to update stockholder nomination procedures and governance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bylaws amended effective April 12, 2023; updates for universal proxy rules and stockholder proposal requirements.","New rules require additional disclosures from nominating stockholders and compliance with Rule 14a-19 for proxy solicitations.","Changes address adjournment due to technical failures, special meeting nomination limits, and director nominees cap.","Bylaws also remove inoperative written consent provisions and add emergency condition procedures for Board meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316632,"accession_number":"0001490978-23-000023","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrödinger FY2022 total revenue $181M (+31%); Q4 revenue $56.8M (+23%); net loss widens to $149M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2022 total revenue $181.0M (+31% YoY); software revenue $135.6M (+20%), drug discovery $45.4M (+84%).","Net loss $149.2M versus $101.2M in 2021; operating expenses $247.8M (+40%).","Q4 total revenue $56.8M (+23%); software revenue $47.8M (+24%), drug discovery $9.0M (+19%).","FY2023 guidance: software revenue growth 13-17%, drug discovery revenue $70-90M, cash burn expected to decline.","Received ~$111.3M cash distribution from Nimbus in Feb 2023; expects ~$36M additional in Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":180955000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334881,"accession_number":"0001490978-22-000011","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrodinger Q3 rev $37M (+24% YoY); Lilly collab up to $425M; FY22 guide narrowed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $37.0M (+24% YoY); drug discovery $12.3M (+121%); software $24.7M (+2%)","Net loss $39.9M vs $35.0M; cash $479M vs $513M at June 30, 2022","Entered collaboration with Lilly; up to $425M in milestones plus tiered royalties","Phase 1 trial of MALT1 inhibitor SGR-1505 open for patient enrollment","FY22 total revenue guide narrowed to $167-175M; software rev lowered to $122-127M; drug discovery raised to $45-48M"],"consensus_eps_estimate":null,"consensus_eps_actual":-1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":124112000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352326,"accession_number":"0001564590-22-029714","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2022-08-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Schrödinger appoints Geoffrey Porges as CFO; severance plan amended","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Porges appointed EVP/CFO effective Aug 18, 2022; previously Vice Chairman at SVB Securities.","Base salary $580k, sign-on bonus $230k (repayable if terminated for cause or resigns within 24 mo).","Granted 180k stock options (25% vest year 1, then monthly over 3 yrs) and 90k performance-based RSUs.","Jenny Herman ceases as interim CFO but remains principal accounting officer.","Executive Severance Plan amended: 9 months salary for non-CIC termination for certain execs; CIC severance multiples increased (CFO: 0.75x to 1.0x; CEO: 1.0x to 1.5x)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352325,"accession_number":"0001564590-22-028003","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrödinger Q2 revenue up 29% YoY to $38.5M; net loss widens to $47.7M, maintains 2022 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Software revenue $30.0M (+25% YoY); drug discovery revenue $8.5M (+48% YoY).","Net loss of $47.7M vs. $35.0M in Q2 2021; gross profit $17.1M (+43%).","Cash, equivalents, and marketable securities ~$513M, down from $529M at March 31, 2022.","IND for MALT1 inhibitor SGR-1505 cleared; Phase 1 trial in B-cell lymphoma expected Q4 2022.","Maintains full-year 2022 guidance: total revenue $161M–$181M, software revenue $126M–$136M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":87132000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369865,"accession_number":"0001193125-22-175530","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2022-06-16T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Schrödinger stockholders approve 2022 Equity Incentive Plan adding up to 15.6M new shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 2022 Equity Incentive Plan, authorizing up to 15,605,822 shares of common stock for awards.","Elected Jeffrey Chodakewitz, Michael Lynton, and Nancy A. Thornberry as Class II directors for three-year terms.","Advisory vote on executive compensation passed with ~44M shares for vs ~2.95M against; broker non-votes ~6.4M.","Stockholders recommended annual say-on-pay frequency; Board intends to hold annual votes going forward.","Ratified KPMG as independent auditor for FY2022 with ~53.1M shares for, ~0.3M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369864,"accession_number":"0001564590-22-020696","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2022-05-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Schrödinger elects Arun Oberoi to Board, effective May 17, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Arun Oberoi elected as class I director; term expires at 2024 annual meeting.","Former EVP Global Sales & Services at Red Hat (acquired by IBM); prior exec roles at HP and Micromuse.","Appointed to Audit Committee; receives initial option for 30,223 shares at $24.77 ($380k value).","Also serves on boards of Proofpoint, Talend S.A., and Deeplite."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369863,"accession_number":"0001564590-22-017846","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrödinger Q1 total revenue up 51% to $48.7M; net loss widens to $34.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Software revenue $33.1M (+26% YoY); drug discovery revenue $15.6M (+169% YoY).","Net loss of $34.5M compared to $0.5M loss in Q1 2021.","Maintains full-year 2022 total revenue guidance of $161M-$181M.","Cash, equivalents, and marketable securities of ~$529M; MALT1 IND on track for H1 2022.","Software gross margin 77%; operating expenses $56.6M, up 41% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":48663000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388988,"accession_number":"0001193125-22-063008","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2022-03-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Joel Lebowitz retires; enters transition and consulting agreements effective Feb 28, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joel Lebowitz retired as CFO and Treasurer effective February 28, 2022.","Receives salary continuation for 9 months post-separation and COBRA premium payments for up to 18 months.","Consulting agreement: $3,500/month for up to 10 hours of services, $350/hour for additional hours.","Stock options continue vesting during the consulting period; exercise period extended to 9 months after termination.","Non-compete obligation under employment agreement extended for 9 months following separation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388987,"accession_number":"0001564590-22-006692","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrödinger Q4 software revenue $38.6M, up 55% YoY; guides 2022 total revenue $161-181M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $46.2M (+40% YoY); software revenue $38.6M (+55% YoY); drug discovery $7.6M.","FY 2021 total revenue $137.9M (+28% YoY); net loss $101.2M vs $26.6M loss in 2020.","2022 guidance: total revenue $161-181M; software $126-136M; drug discovery $35-45M; gross margin mid-70s%.","Karen Akinsanya promoted to president of R&D; MALT1 IND H1 2022; Phase 1 study in H2 2022.","Cash $579M; ACV $112.1M (+22% YoY); 190 customers >$100k ACV."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":137931000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406915,"accession_number":"0001193125-21-363016","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2021-12-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Schrödinger CFO Joel Lebowitz to retire; Jenny Herman appointed interim principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joel Lebowitz notified of retirement as CFO, effective Feb 28, 2022.","Board appointed Jenny Herman as interim principal financial officer, effective Mar 1, 2022.","Herman currently Senior VP, Finance and Corporate Controller since Oct 2020.","Herman is a CPA and has been with the company since 2002."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406914,"accession_number":"0001564590-21-056175","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrödinger Q3 revenue $29.9M (+16% YoY); net loss $35M vs $3.9M income; lowers drug discovery revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $29.9M (+16% YoY); software revenue $24.3M (+6%), drug discovery $5.6M (up from $2.9M).","Net loss $35.0M vs net income $3.9M in Q3 2020; operating expenses rose to $45.8M from $30.7M.","Cash and marketable securities $600.2M as of Sep 30, 2021, down from $616.6M at Jun 30.","Full-year drug discovery revenue guidance revised to $22-24M from $22-32M; software guidance maintained at $102-110M.","Selected development candidate for CDC7 inhibitor; MALT1 IND submission expected H1 2022; pipeline expanded to five programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":91761000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425912,"accession_number":"0000950123-21-010437","cik":1490978,"company_name":"Schrodinger, Inc.","ticker":"SDGR","form_type":"8-K","filed_at":"2021-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Schrödinger Q2 revenue up 29% to $29.8M; net loss widens to $34.6M on investment spend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $29.8M (+29% YoY); software revenue $24.1M (+15% YoY); drug discovery revenue $5.7M.","Net loss $34.6M vs $3.4M loss Q2 2020, driven by fair-value adjustments and R&D investments.","Announced global oncology collaboration with Zai Lab; eligible for up to ~$338M milestones and U.S. profit share.","Pipeline advancing: plans to submit up to three INDs to FDA in 2022, first IND expected H1 2022.","Full-year 2021 guidance maintained: total revenue $124M-$142M, software revenue $102M-$110M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":61911000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1022926732.4879153,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}